SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ind-Swift in jubilant mood on getting nod for proposed scheme of amalgamation

21 Nov 2011 Evaluate

Ind-Swift is currently trading at Rs 28.70, up by 1.55 points or 5.71% from its previous closing of Rs 27.15 on the BSE.

The scrip opened at Rs 27.75 and has touched a high and low of Rs 28.80 and Rs 27.75 respectively. So far 30518 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 40.00 on 18-Apr-2011 and a 52 week low of Rs 23.40 on 22-Aug-2011.

Last one week high and low of the scrip stood at Rs 32.45 and Rs 26.75 respectively. The current market cap of the company is Rs 114.51 crore.

The promoters holding in the company stood at 43.60% while Institutions and Non-Institutions held 4.04% and 52.36% respectively.

Ind-Swift has received an approval for the proposed scheme of amalgamation of Essix Biosciences and Dashmesh Medicare with itself. The board at its meeting held on November 14, 2011 has granted its in-principle approval for the same.

The amalgamation will be done under section 391 to 394 of the Companies Act, 1956, subject to appropriate statutory and regulatory approvals.

Essix Biosciences and Dashmesh Medicare are both unlisted entities.

Ind-Swift manufactures and markets finished dosage forms, through its different divisions, focusing on the needs of various therapeutic segments. The divisions include Super Speciality, Animal Division, Daignozis, Institutions, Agile, Bio Sciences, Ethical, Health Care, Max Care, Mega care, Neuro and Resurgence.

Ind-Swift - Amalgama Share Price

15.70 0.00 (0.00%)
13-Aug-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×